Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care

Two-drug regimens (2DR) may address drug-drug interactions and toxicity concerns. Dolutegravir/lamivudine (DTG/3TC) 2DR was approved in the US for both treatment-naïve and treatment-experienced individuals with a viral load

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	HIV/AIDS (Auckland) 2024-01, Vol.16, p.133-140
Hauptverfasser:	Pierone, Jr, Gerald, Brunet, Laurence, Fusco, Jennifer S, Henegar, Cassidy E, Sarkar, Supriya, Van Wyk, Jean, Vannappagari, Vani, Wohlfeiler, Michael B, Fusco, Gregory P
Format:	Artikel
Sprache:	eng
Schlagworte:	antiretroviral therapy Biological products industry cohort Drug approval electronic health records Emtricitabine Highly active antiretroviral therapy HIV (Viruses) Medical records Patient outcomes Rilpivirine suppressed viral load Virus diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Two-drug regimens (2DR) may address drug-drug interactions and toxicity concerns. Dolutegravir/lamivudine (DTG/3TC) 2DR was approved in the US for both treatment-naïve and treatment-experienced individuals with a viral load
ISSN:	1179-1373 1179-1373
DOI:	10.2147/HIV.S452130